Aminobutyrates

• 

  Subject Areas on Research

  • Activation of metabotropic glutamate receptor 7 in spinal cord inhibits pain and hyperalgesia in a novel formalin model in sheep. 
  • Angiotensin Receptor-Neprilysin Inhibition Based on History of Heart Failure and Use of Renin-Angiotensin System Antagonists. 
  • Angiotensin receptor neprilysin inhibition in heart failure: mechanistic action and clinical impact. 
  • Association Between Sacubitril/Valsartan Initiation and Health Status Outcomes in Heart Failure With Reduced Ejection Fraction. 
  • Calcium-dependent gamma-aminobutyrate release by interneurons of rat hippocampal regions: lesion-induced plasticity. 
  • Can 2 Pills a Day Keep Readmission Away?: Sacubitril/Valsartan to Reduce 30-Day Heart Failure Readmissions. 
  • Cardiovascular biomarkers in patients with acute decompensated heart failure randomized to sacubitril-valsartan or enalapril in the PIONEER-HF trial. 
  • Characteristics and Treatments of Patients Enrolled in the CHAMP-HF Registry Compared With Patients Enrolled in the PARADIGM-HF Trial. 
  • Circulating Neprilysin in Patients With Heart Failure and Preserved Ejection Fraction. 
  • Clinical Outcomes in Patients With Acute Decompensated Heart Failure Randomly Assigned to Sacubitril/Valsartan or Enalapril in the PIONEER-HF Trial. 
  • Combined neprilysin and renin-angiotensin system inhibition in heart failure with reduced ejection fraction: a meta-analysis. 
  • Comparative proteomic analysis of differentially expressed proteins in β-aminobutyric acid enhanced Arabidopsis thaliana tolerance to simulated acid rain. 
  • Comparison of Hydralazine/Nitrate and Angiotensin Receptor Neprilysin Inhibitor Use Among Black Versus Nonblack Americans With Heart Failure and Reduced Ejection Fraction (from CHAMP-HF). 
  • Concurrent measurements of blood flow and transcapillary transport in xenotransplanted human gliomas in immunosuppressed rats. 
  • Early Adoption of Sacubitril/Valsartan for Patients With Heart Failure With Reduced Ejection Fraction: Insights From Get With the Guidelines-Heart Failure (GWTG-HF). 
  • Effect of glutamate analogues on brain tumor cell lines. 
  • From Theory to Practice: The Use of Real-World Data to Evaluate New Heart Failure Therapies. 
  • GABA, picrotoxin and retinal sensitivity. 
  • Glutamate as transmitter of hippocampal perforant path. 
  • Growth inhibitory effects of aromatic fatty acids on ovarian tumor cell lines. 
  • High-sensitivity rod photoreceptor input to the blue-yellow color opponent pathway in macaque retina. 
  • In HF with LVEF ≤ 42.5%, sacubitril-valsartan vs RAS inhibitors reduced a composite of CV death or HF hospitalization. 
  • In-hospital initiation of sacubitril/valsartan in acute decompensated heart failure: being in the right place at the right time. 
  • Initiation of Angiotensin-Neprilysin Inhibition After Acute Decompensated Heart Failure: Secondary Analysis of the Open-label Extension of the PIONEER-HF Trial. 
  • Initiation, Continuation, Switching, and Withdrawal of Heart Failure Medical Therapies During Hospitalization. 
  • LCZ696: too good to be true? 
  • Medications Are Important for Sudden Cardiac Death Prevention But So Is the Implantable Cardioverter-Defibrillator. 
  • Metabolism of the aspartyl moiety of N-acetyl-L-aspartic acid in the rat brain. 
  • Multifocal electroretinogram in rhodopsin P347L transgenic pigs. 
  • PROVIDE-HF primary results: Patient-Reported Outcomes inVestigation following Initiation of Drug therapy with Entresto (sacubitril/valsartan) in heart failure. 
  • Patient, Provider, and Practice Characteristics Associated With Sacubitril/Valsartan Use in the United States. 
  • Pharmacologically defined components of the normal porcine multifocal ERG. 
  • Potential Mortality Reduction With Optimal Implementation of Angiotensin Receptor Neprilysin Inhibitor Therapy in Heart Failure. 
  • Racial and Ethnic Differences in Biomarkers, Health Status, and Cardiac Remodeling in Patients With Heart Failure With Reduced Ejection Fraction Treated With Sacubitril/Valsartan. 
  • Rationale and design of the comParIson Of sacubitril/valsartaN versus Enalapril on Effect on nt-pRo-bnp in patients stabilized from an acute Heart Failure episode (PIONEER-HF) trial. 
  • Relationship Between Hospital Characteristics and Early Adoption of Angiotensin-Receptor/Neprilysin Inhibitor Among Eligible Patients Hospitalized for Heart Failure. 
  • Reply: Adoption of Sacubitril/Valsartan Must Take Into Account Different Heart Failure Patient Types. 
  • Representativeness of the PIONEER-HF Clinical Trial Population in Patients Hospitalized With Heart Failure and Reduced Ejection Fraction. 
  • Reverse Cardiac Remodeling and Outcome After Initiation of Sacubitril/Valsartan. 
  • Sacubitril/Valsartan in Advanced Heart Failure With Reduced Ejection Fraction: Rationale and Design of the LIFE Trial. 
  • Scope of Sacubitril/Valsartan Eligibility After Heart Failure Hospitalization: Findings From the GWTG-HF Registry (Get With The Guidelines-Heart Failure). 
  • Should providers prescribe sacubitril/valsartan based on trial eligibility, approval indication, or guideline recommendations? 
  • Subcellular distribution of transmitter-related enzyme activities in discrete areas of the rat dentate gyrus. 
  • The ABCs of managing systolic heart failure: Past, present, and future. 
  • The Use of Sacubitril/Valsartan for Hospitalized Heart Failure-Why Do We Care About Cost and Value? 
• 

  Keywords of People

  • Field, Greg D., Assistant Professor of Neurobiology, Neurobiology